1. Home
  2. ALNY vs FCNCA Comparison

ALNY vs FCNCA Comparison

Compare ALNY & FCNCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALNY
  • FCNCA
  • Stock Information
  • Founded
  • ALNY 2002
  • FCNCA 1898
  • Country
  • ALNY United States
  • FCNCA United States
  • Employees
  • ALNY N/A
  • FCNCA N/A
  • Industry
  • ALNY Biotechnology: Pharmaceutical Preparations
  • FCNCA Major Banks
  • Sector
  • ALNY Health Care
  • FCNCA Finance
  • Exchange
  • ALNY Nasdaq
  • FCNCA Nasdaq
  • Market Cap
  • ALNY 35.0B
  • FCNCA 29.3B
  • IPO Year
  • ALNY 2004
  • FCNCA N/A
  • Fundamental
  • Price
  • ALNY $250.59
  • FCNCA $2,049.25
  • Analyst Decision
  • ALNY Buy
  • FCNCA Buy
  • Analyst Count
  • ALNY 23
  • FCNCA 10
  • Target Price
  • ALNY $305.86
  • FCNCA $2,397.70
  • AVG Volume (30 Days)
  • ALNY 687.2K
  • FCNCA 66.5K
  • Earning Date
  • ALNY 02-13-2025
  • FCNCA 01-24-2025
  • Dividend Yield
  • ALNY N/A
  • FCNCA 0.38%
  • EPS Growth
  • ALNY N/A
  • FCNCA N/A
  • EPS
  • ALNY N/A
  • FCNCA 189.38
  • Revenue
  • ALNY $2,248,243,000.00
  • FCNCA $9,329,000,000.00
  • Revenue This Year
  • ALNY $22.50
  • FCNCA N/A
  • Revenue Next Year
  • ALNY $30.54
  • FCNCA $2.52
  • P/E Ratio
  • ALNY N/A
  • FCNCA $10.82
  • Revenue Growth
  • ALNY 22.97
  • FCNCA 22.69
  • 52 Week Low
  • ALNY $141.98
  • FCNCA $1,505.73
  • 52 Week High
  • ALNY $304.39
  • FCNCA $2,412.93
  • Technical
  • Relative Strength Index (RSI)
  • ALNY 39.26
  • FCNCA 36.08
  • Support Level
  • ALNY $246.61
  • FCNCA $2,100.05
  • Resistance Level
  • ALNY $268.52
  • FCNCA $2,190.57
  • Average True Range (ATR)
  • ALNY 8.23
  • FCNCA 45.68
  • MACD
  • ALNY -3.61
  • FCNCA -11.47
  • Stochastic Oscillator
  • ALNY 12.20
  • FCNCA 0.00

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

About FCNCA First Citizens BancShares Inc.

First Citizens BancShares Inc is the bank holding company of First Citizens Bank & Trust Company. FCB was founded as the Bank of Smithfield in North Carolina and has expanded through both de novo branching and acquisitions. FCB currently operates in nearly half of the continental United States, but principally takes deposits in the Carolinas. The bank's operations have historically been influenced by the Holding family, which has traditionally held executive and director positions, as well as controlling a large percentage of its outstanding stock. FCB provides a wide range of retail and commercial banking services, including traditional lending and deposit-taking, as well as trust and wealth management. FCB's main source of revenue is net interest income.

Share on Social Networks: